Quality characteristics of low fat chicken sausages fortified with pearl millet

The present study was conducted to optimise the level of dietary fibre source viz. pearl millet flour at 5.0, 10.0 and 15.0% levels (BT1, BT2 and BT3) in formulation of chicken sausage. The emulsion pH, emulsion stability, product pH, cooking yield, moisture, ash content, fat retention and moisture retention values increased significantly (P<0.05), whereas, protein, emulsion fat and product fat content decreased significantly (P<0.05) with increase in level of pearl millet flour. There was no significant difference in water activity values between the control and treatments. Among the textural and colour parameters, hardness, springiness, cohesiveness, gumminess, chewiness, resilience and redness values increased significantly, whereas, lightness and yellowness values decreased significantly (P<0.05) in treatments. The scores of all sensory attributes decreased significantly (P<0.05) with pearl millet flour incorporation in chicken sausage. Among the treatments, the scores of BT3 were significantly lower than BT1; however, BT2 had comparable overall acceptability sensory scores with BT1 and BT3. Therefore, BT2- chicken sausage incorporated with 10.0% pearl millet was selected as the best treatment

QUALITY IMPROVEMENT OF POULTRY SLAUGHTER HOUSE BYPRODUCTS BASED PET FOOD WITH INCORPORATION OF FIBER-RICH VEGETABLE POWDER

The present study was conducted to evaluate the effect of fiber-rich vegetables on the quality characteristics of poultry slaughterhouse byproducts incorporated in pet food. Poultry byproducts incorporated in pet food were treated with different fiber-rich vegetables, viz. carrot and French beans powder separately at three suitable concentrations i.e. 5%, 10%, and 15% replacing freshly grated cruciferous vegetables and baked in a hot air oven at 1500 C for 20-25 minutes. Carrot powder @10% (CR) and French bean powder @10% (FB) were found optimum based on the palatability test. Finally, CR and FB were compared with control (BP) pet food for various physico-chemical properties and palatability tests. The pH values of BP and CR were significantly (p<0.05) higher than FB, whereas the baking yield values of CR were significantly (p<0.05) higher than BP and FB. Moisture, ash content, and water activity values of CR and FB were significantly (p<0.05) higher, and protein, as well as fat content, were significantly (p<0.05) lower than BP. There were no significant differences in springiness, cohesiveness, and resilience values between control and treatments. Hardness values of BP were significantly (p<0.05) higher whereas gumminess and chewiness values were significantly (p<0.05) lower than CR and FB. There was no significant difference in any textural parameter between CR and FB. Lightness and yellowness values of CR were significantly (p<0.05) higher whereas redness values of FB were significantly (p<0.05) lower than BP and other treatments. The scores of all palatability attributes of FB were significantly (p<0.05) lower than BP and CR, whereas no significant difference was observed between BP and CR. Therefore, Poultry byproducts incorporated with pet food with 10% carrot powder were selected as the best treatment

Preparation and evaluation of mouth dissolving tablets of meloxicam

The aim of the present study was to develop evaluate mouth dissolving tablet of meloxicam. Drug delivery systems became sophisticated as pharmaceutical scientists acquire a better understanding of the physicochemical and biochemical parameters pertinent to their performance. Over the past three decades, mouth dissolving or orally disintegrating tablets have gained considerable attention as a preferred alternative to conventional tablets due to better patient compliance. The most preferrable route of drug administration (e.g. oral) is limited to drug candidate that show poor permeability across the gastric mucosa and those, which are sparingly soluble. A large majority of the new chemical entities and many new existing drug molecules are poorly soluble, thereby limiting their potential uses and increasing the difficulty of formulating bioavailable drug products,so lastlly the purpose of this study was to grow mouth dissolve tablets of Meloxicam. Meloxicam is a newer selective COX-1 inhibitor. These tablets were prepared by wet granulation procedure. The tablets were evaluated for % friability, wetting time and disintegration time. Sublimation of camphor from tablets resulted in better tablets as compared to the tablets prepared from granules that were exposing to vacuum. The systematic formulation approach helped in understanding the effect of formulation processing variables.Keywords: Mouth dissolving tablet; Maloxicam; Bioavailability; NSAI

Preparation and evaluation of mouth dissolving tablets of meloxicam

The aim of the present study was to develop evaluate mouth dissolving tablet of meloxicam. Drug delivery systems became sophisticated as pharmaceutical scientists acquire a better understanding of the physicochemical and biochemical parameters pertinent to their performance. Over the past three decades, mouth dissolving or orally disintegrating tablets have gained considerable attention as a preferred alternative to conventional tablets due to better patient compliance. The most preferrable route of drug administration (e.g. oral) is limited to drug candidate that show poor permeability across the gastric mucosa and those, which are sparingly soluble. A large majority of the new chemical entities and many new existing drug molecules are poorly soluble, thereby limiting their potential uses and increasing the difficulty of formulating bioavailable drug products,so lastlly the purpose of this study was to grow mouth dissolve tablets of Meloxicam. Meloxicam is a newer selective COX-1 inhibitor. These tablets were prepared by wet granulation procedure. The tablets were evaluated for % friability, wetting time and disintegration time. Sublimation of camphor from tablets resulted in better tablets as compared to the tablets prepared from granules that were exposing to vacuum. The systematic formulation approach helped in understanding the effect of formulation processing variables.Keywords: Mouth dissolving tablet; Maloxicam; Bioavailability; NSAI

Varied presentations of moyamoya disease in a tertiary care hospital of north-east India

Introduction: Moyamoya disease is a chronic progressive cerebrovascular disorder, characterized by stenosis or occlusion of bilateral internal carotid arteries (ICAs), anterior cerebral arteries (ACAs) and middle cerebral arteries (MCAs), accompanied by a collateral network of vessels formed at the base of the brain. Ischemia and intracranial hemorrhage are the common typical manifestations. However moyamoya disease has been associated with atypical presentations like headache, seizures and involuntary movements. Although frequently reported from Asian countries like Japan, China and Korea, only few studies reported on clinical manifestations of moyamoya disease from India. Objectives: To study the varied presentations of moyamoya disease in a tertiary care hospital of north-east India. Material and Methods: Relevant investigations were done to rule out other causes of moyamoya syndrome. Results: We report 6 cases of moyamoya disease with varied presentations from a tertiary care referral government hospital. Case 1, 2 and 6 presented with alternating hemiparesis. Case 3 had amaurosis fugax. Case 4 had history suggestive of ischemic stroke and presented with hemichorea. Case 4 had focal seizure as the only manifestation. Cases 4 and 5 notably had stenosis of posterior cerebral artery (PCA) in addition to stenosis of bilateral ICAs, ACAs and MCAs. Conclusion: Owing to its low incidence in India, moyamoya disease is easily overlooked as a possible diagnosis. However, because of its progressive nature, it is imperative to diagnose this disease early and offer surgical treatment to the patients

Myopathies of endocrine disorders: A prospective clinical and biochemical study

Introduction: Major categories of endocrine myopathy include those associated with: Adrenal dysfunction (as in Cushing′s disease or steroid myopathy); thyroid dysfunction (as in myxedema coma or thyrotoxic myopathy); vitamin D deficiency; parathyroid dysfunction; and pituitary dysfunction. Steroid myopathy is the most common endocrine myopathy. Objective: To study the etiology, varied presentations, and outcome after therapy of patients with endocrine myopathies. Materials and Methods: Myopathy was evaluated by the standard clinical procedures: Detailed clinical history, manual muscle strength testing, and creatine phosphokinase (CPK). Endocrine disorders were diagnosed as per clinical features and biochemical parameters. The treatment was given to patients as per underlying endocrine disease. Myopathy was assessed before and after treatment. Results: Out of the 37 patients who were diagnosed with endocrine myopathies, thyroid dysfunction was the most common cause (17 cases), followed by vitamin D deficiency in nine, adrenal dysfunction in six, parathyroid dysfunction in three, and pituitary dysfunction in two. Some patients had atypical presentation (repeated falls in one, tongue fasciculations in one, neck weakness in five, one with ptosis and facial weakness, asymmetrical onset in one, and calf hypertrophy in one. The serum creatine kinase (CK) concentration did not correlate with muscle weakness. Following the treatment regimen which was specific for a given myopathy, 26 patients recovered fully. Conclusion: We found varied clinical presentations of endocrine myopathies. All the patients with neuromuscular complaints should be investigated for endocrine causes because significant number of them recovers fully with specific treatment